Hudi enteric-coated capsule and its active constituent polydatin suppress Th1/Th17-mediated intestinal inflammation by modulating the KEAP1-NFE2L2 signaling pathway
Precision Clinical Medicine · 30.07.2026 · 9 (3)
DOI: 10.1093/pcmedi/pbag018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Precision Clinical Medicine, online erschienen am 03.07.2026. Verfasst von Xiaohan Wu und 12 weiteren Autor:innen. Beteiligte Einrichtung: Xinxiang Key Laboratory of Precision Diagnosis and Treatment for Inflammatory Bowel Disease, Henan Key Laboratory of the Prevention and Treatment of …. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Henan Province, National Key Research and Development Program of China.
Abstract (Originalsprache)
Objective
To investigate the anti-inflammatory mechanisms of Hudi enteric-coated capsule (HDEC) and its major bioactive constituent, polydatin, in ulcerative colitis (UC).
Methods
Mouse models of colitis were established by transplantation adoptive transfer of CD45RBhighCD4+ T cells and treated with or without HDEC/polydatin. Therapeutic efficacy was evaluated by assessing disease activity, colon length, and histopathological damage. The differentiation of Th1, Th17, and Treg cells was analyzed using quantitative real-time polymerase chain reaction and flow cytometry. In vitro cultures of mouse and human CD4+ T cells were utilized to assess the immunomodulatory activity. RNA sequencing, Western blotting, and immunofluorescence were used to explore the underlying mechanism. Molecular docking, molecular dynamics, and surface plasmon resonance (SPR) assays were employed to confirm the interaction between polydatin and KEAP1.
Results
Treatment with HDEC and polydatin significantly ameliorated murine colitis and mucosal damage. Mechanistically, polydatin directly binds to KEAP1 to promote NFE2L2 nuclear translocation. This NFE2L2 activation reduces intracellular oxidative stress, thereby inhibiting pathogenic Th1/Th17 differentiation and enhancing Treg generation. Importantly, these effects were consistently validated in human CD4+ T cells and UC mucosal tissues.
Conclusion
HDEC and polydatin alleviate UC by targeting the KEAP1-NFE2L2 axis to reduce oxidative stress, thereby restoring the Th1/Th17/Treg balance. This highlights polydatin as a promising KEAP1-targeting agent with strong translational potential.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Xinxiang Key Laboratory of Precision Diagnosis and Treatment for Inflammatory Bowel Disease, Henan Key Laboratory of the Prevention and Treatment of Gastrointestinal Cancer, Department of Gastroenterology, the First Aff…
- Center for Inflammatory Bowel Disease Research and Department of Gastroenterology, Affiliated Suzhou Hospital of Nanjing Medical University, Suzhou Municipal Hospital, Gusu School, Nanjing Medical University, Suzhou 215…
- Department of Gastroenterology, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, China.
- Department of Gastroenterology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
- The First School of Clinical Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
- Innovative Technology Center, The Ministry of Science and Technology (MOST), Beijing 100862, China.
ORCID-Profile: Zhanju Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Henan Province
- National Key Research and Development Program of China
- Xinxiang Medical University
Zitieren
APA
Wu, X., Shi, L., Zhu, L., Mao, T., Wang, Z., Kou, F., Han, X., Gao, H., Chen, X., Li, X., Chang, T., Li, J., & Liu, Z. (2026). Hudi enteric-coated capsule and its active constituent polydatin suppress Th1/Th17-mediated intestinal inflammation by modulating the KEAP1-NFE2L2 signaling pathway. Precision Clinical Medicine, 9(3). https://doi.org/10.1093/pcmedi/pbag018
Vancouver
Wu X, Shi L, Zhu L, Mao T, Wang Z, Kou F, et al. Hudi enteric-coated capsule and its active constituent polydatin suppress Th1/Th17-mediated intestinal inflammation by modulating the KEAP1-NFE2L2 signaling pathway. Precision Clinical Medicine. 2026;9(3). doi:10.1093/pcmedi/pbag018
BibTeX
@article{Wu2026,
author = {Wu, Xiaohan and Shi, Lei and Zhu, Lei and Mao, Tangyou and Wang, Zhibin and Kou, Fushun and Han, Xiao and Gao, Han and Chen, Xiaohua and Li, Xianxin and Chang, Tingmin and Li, Junxiang and Liu, Zhanju},
title = {Hudi enteric-coated capsule and its active constituent polydatin suppress Th1/Th17-mediated intestinal inflammation by modulating the KEAP1-NFE2L2 signaling pathway},
journal = {Precision Clinical Medicine},
year = {2026},
volume = {9},
number = {3},
doi = {10.1093/pcmedi/pbag018}
}
EUVIMED